Patent
A vaccine for the prevention of anthrax, including a live, attenuated Salmonella and at least one nucleotide sequence encoding anthrax protective antigen (PA) or a fragment thereof and a nonlethal mutated form of anthrax lethal factor (LF) or a fragment thereof. In another implementation, the vaccine is constituted for the prevention of anthrax and at least one additional pathogen, as including a live, attenuated Salmonella and at least one nucleotide sequence encoding at least a fragment of a nonlethal mutated form of anthrax lethal factor (LF) and at least one nucleotide sequence encoding at least a fragment of an antigen of an additional pathogen. Vaccines of such types can be administered to stimulate antibody response in a subject, whereby the antibody response confers immunity to the subject.
1. A vaccine for the prevention of anthrax comprising a live, attenuated Salmonella comprising a nucleotide sequence encoding a fusion protein, wherein the nucleotide sequence comprises a sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 24.
2. A vaccine for the prevention of anthrax comprising a live, attenuated Salmonella comprising a nucleotide sequence encoding a fusion protein, wherein the fusion protein comprises a sequence selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 25.